Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation

49Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Prevention of cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) generally involves preemptive treatment of recognized infection before the onset of overt CMV-associated disease. The success of this method depends on efficient recognition of infection and intervention before the disease progresses. Reliable tests for such diagnosis include blood culture, antigenemia assays, polymerase chain reaction assays, and other DNA sequence- or RNA sequence-based assays. For selected high-risk patients, such as patients receiving T cell-depleted hematopoietic stem cell transplants, prophylactic use of antiviral agents before the onset of CMV infection is recommended. The ability to monitor the immunological status of the patient relative to CMV-specific immunity is increasing in importance. Ultimately, the solution to the problem of efficient prevention of CMV infection in this population will require combined antiviral chemotherapy and improved reconstitution of CMV immunity.

References Powered by Scopus

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of t-cell clones from the donor

1640Citations
N/AReaders
Get full text

Risk factors for cytomegalovirus infection after human marrow transplantation

727Citations
N/AReaders
Get full text

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants

616Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies

393Citations
N/AReaders
Get full text

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy

151Citations
N/AReaders
Get full text

Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection

121Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zaia, J. A. (2002). Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clinical Infectious Diseases, 35(8), 999–1004. https://doi.org/10.1086/342883

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

54%

Professor / Associate Prof. 3

23%

Researcher 2

15%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

69%

Pharmacology, Toxicology and Pharmaceut... 2

15%

Engineering 1

8%

Agricultural and Biological Sciences 1

8%

Save time finding and organizing research with Mendeley

Sign up for free